Eight babies born in England using a three-parent IVF technique appear healthy, according to a study published in 2023 [1], [2].
This development marks a significant milestone in genetic medicine. By using mitochondrial replacement therapy, doctors can prevent mothers from passing fatal mitochondrial DNA mutations to their children [1], [3].
The procedure involves replacing faulty mitochondria from the mother's egg with healthy mitochondria from a female donor. This ensures the child inherits the nuclear DNA of both parents, but the mitochondrial DNA of the donor [3], [4]. This specific method is designed to eliminate the risk of inheriting debilitating diseases that affect energy production in the cells [4].
The results from the 2023 study provide early evidence that the therapy is safe [1], [2]. The eight infants born via this method have shown positive early signs of health [2], [3].
This medical application follows a long legislative process in the United Kingdom. The UK Parliament approved the use of mitochondrial replacement therapy 11 years ago [1]. The approval paved the way for clinical trials and the subsequent births of children who would otherwise have been at risk of severe genetic disorders [4].
Researchers continue to monitor the children to ensure long-term safety and efficacy. The study serves as a benchmark for other nations considering the adoption of similar genetic therapies to combat hereditary diseases [3].
“Eight babies born in England using a three-parent IVF technique appear healthy”
The successful birth and early health of these children validate a decade of legislative and scientific preparation in the UK. By proving that mitochondrial replacement therapy can effectively block the transmission of fatal mutations without immediate adverse effects, this study provides a clinical foundation for the global expansion of 'three-parent' IVF to treat rare genetic conditions.
